TPB FDA concerns for nicotine pouches

What happened: Turning Point Brands (TPB), a tobacco company, saw its stock plummet 15.5% this week due to FDA concerns over its fast-growing nicotine pouch brand, FRE. The FDA's hesitation to approve new pouch types, citing safety concerns for children, has negatively impacted TPB's share price, which is now down 50% from its highs. Meanwhile, Alliance Global maintained a 'Buy' rating on TPB but reduced its price target to $130 from $135, citing cut forecasts ahead of the first-quarter results. Conversely, a new marketing deal with a suitable business partner boosted TPB's stock on April 23.

Market impact: The FDA's regulatory uncertainty has driven a significant sell-off in TPB's stock, affecting the tobacco and nicotine pouch sectors. The marketing deal, however, has temporarily reignited investor interest in the company. The FDA's stance on nicotine pouches may influence other tobacco companies exploring similar product lines, such as Swedish Match and Imperial Brands.

What to watch next: Investors should closely monitor TPB's first-quarter earnings, scheduled for release on May 10, to gauge the financial impact of FDA delays and the marketing deal. Additionally, the FDA's future regulatory decisions on nicotine pouches will determine the trajectory of TPB's stock and the broader nicotine pouch market. Lastly, keep an eye on TPB's stock price around the $130 level, as it approaches Alliance Global's reduced price target.